Summary We investigated how residual tumour burden after cytoreductive surgery was related to the occurrence of acute and delayed nausea and vomiting in 101 ovarian cancer patients receiving their first chemotherapy course. The anti-emetic treatment included ondansetron combined with dexamethasone or placebo. After chemotherapy all patients received ondansetron only for 5 days. Two categories of tumour burden (TB) were formed according to the diameter of the greatest residual tumour (<2 cm = minimal TB and > 2 cm= large TB). Self-reports of nausea and vomiting were obtained for 15 days. Other potential predictor variables were assessed and included in multivariate analyses. Patients with large compared with minimal TB had more delayed emesis, especially on days 2-7. They also had more acute nausea. The aggravating effect associated with large residual TB was more evident in patients >55 years. During the second week after the chemotherapy the occurrence of nausea was higher in patients >55 years than in those <55 years. This was seen primarily in patients with large residual TB. Predictors for no delayed emesis at all were anti-emetic treatment with dexamethasone, minimal tumour burden, low neuroticism and no history of motion sickness. The increased risk of 'persistent' delayed nausea and vomiting seen in older patients with large tumour burden may have important clinical implications and warrants further attention.
Delayed emesis is a major problem for many patients. It starts by definition 24 h after the beginning of the chemotherapy and may last for several days (Joss et al., 1994; Sorbe et al., 1994) . As opposed to the model for acute emesis with an assumed single dominating mechanism (release of 5-HT acting on abdominal 5-HT3 receptors resulting in activation of vagal afferents), several pathways have been proposed for delayed nausea and vomiting. Cerebral oedema, disordered gut function and cell degradation products are factors suggested as related to delayed emesis but the empirical evidence for any mechanism is sparse (Andrews and Davis, 1993) .
Identifying predictors for delayed nausea and vomiting may aid in the understanding of the pathogenesis of the disorder and in optimising the anti-emetic treatment. The dose of cisplatin and preceding acute emesis or emesis during previous cycles have been established as prognostic factors for delayed emesis (du Bois et al., 1992; Group for Antiemetic Research, 1994; Roila et al., 1991) . High pretreatment noradrenaline excretion as well as low cortisol excretion have been associated with nausea or vomiting occurring more than 24 h after the start of the chemotherapy Hursti et al., 1993) . In some studies gender has been reported to affect delayed nausea (Kaizer et al., 1994; Roila et al., 1991) or vomiting (du Bois et al., 1992) but in other reports no significant association was found (Italian Group for Antiemetic Research, 1994; Carmichael et al., 1994; Gandara et al., 1993; Lindley et al., 1989) . One study reported an association between previous motion sickness and delayed nausea (Kaizer et al., 1994) .
Summing up, only a few patient characteristics have so far been found to modify delayed nausea and vomiting. However, most of the studies accomplished were not primarily designed to identify predictors of delayed emesis.
In the light of the suggested mechanisms for delayed Some other characteristics previously reported as associated with chemotherapy-related nausea and vomiting were also assessed (Andrykowski and Gregg, 1992; Hursti et al., 1992 Hursti et al., , 1994 Martin and Diaz-Rubio, 1990; Morrow, 1985) . These were age, history of nausea and vomiting in general and in specific situations (motion sickness, nausea during pregnancy, nausea related to alcohol consumption), trait and state anxiety (Spielberger et al., 1968) , neuroticism (Eysenck and Eysenck, 1964) and autonomic perception (Borcovec, 1976) . The purpose was to identify possible confounding factors for the findings concerning tumour burden.
Statistics
In the statistical analyses patients with minimal tumour burden (i.e. <2 cm) were compared with those having large tumour burden (i.e. 2 cm). Ratio of proportions (RP) was used to describe the association between the studied factors and nausea or vomiting. It was calculated as the ratio between the proportions of patients with no nausea or no emetic episodes (i.e. complete response) in the groups of interest. To adjust for the differences in anti-emetic treatment and the possible confounding effect from another studied factor, data were stratified and a weighted ratio of Impact of tumour burden on emesis TJ Hursti et al 9 1115 proportions was computed with a method described by Ahlbom (1990) . Calculation of 95% confidence intervals was performed based on a variance described by Greenland and Robins (1985) . Ratio of proportions provides a very comprehensible measure of effect. However, since the method we used allowed a simultaneous adjustment only for a limited number of other variables, we also performed logistic regression analyses with tumour burden, all the patient characteristics (see Methods) and anti-emetic treatment entered in one block. As a complement to the day-byday analyses, we sought to predict the total anti-emetic response in the entire delayed phase. For that purpose the outcome was defined as a binary response based on whether the patient had experienced emetic episodes and nausea, respectively, during any of the days 1-14). Associations between tumour burden and other patient characteristics were analysed by x2 test where continuous variables were dichotomised by a median-split approach. Prechemotherapy VAS ratings were analysed by Student's t-test and x2 test.
Results
With the exception of age, groups with minimal compared with large tumour burden were well balanced concerning patient and treatment characteristics (all X2(l) < 1.4; NS) (Table I) . Sixty-eight per cent of the patients with large tumour burden were above the median age (i.e. > 55 years) as compared with 38% among patients with minimal tumour burden (X2(1)=8.7; P=0.003). Nausea and vomiting were similar in the groups of patients having received their chemotherapy on a single day compared with a 2 day treatment.
Effects on emetic episodes Figure 1 displays the proportions of patients free from emetic episodes as a function of tumour burden. A quite consistent trend showing that the prevalence of emetic episodes was higher among patients with large tumour burden (i.e. >2 cm in greatest diameter) was observed throughout the assessment period. Ratios of proportions, adjusted for age and antiemetic treatment, were significant for days 3 A statistically non-significant initial trend for more frequent emetic episodes in older patients was observed. Ratio of proportions adjusted for tumour burden and antiemetic treatment was 1.4 (0.9-2.2) for the cisplatin day and 1.2 (0.9-1.8) for day 1 after chemotherapy.
The logistic regression analyses with all the predictor variables entered in one block showed that tumour burden significantly predicted emetic episodes during days 2-3 and 5 -7 (P <0.05) and that the prediction was marginally significant for day 4 (P=0.07) and day 8 (P=0.055). The same method was used to predict the total anti-emetic response in the delayed phase (i.e. no delayed emesis on any day) and resulted in the following statistically significant predictors: anti-emetic treatment with dexamethasone (P=0.016), minimal tumour burden (P=0.021), low neuroticism (P=0.03) and no previous history of motion sickness (P = 0.033). Among patients with large tumour burden 70.7% experienced delayed emesis compared with 46.7% of those with minimal tumour burden [RP 1.5 (1.1-2.1)]. The analysis of total anti-emetic response relies actually on days 1 to 4 since no patient had her first day of delayed emesis later than day 4.
Effects on nausea
Significantly more patients with large tumour burden reported nausea on the chemotherapy day compared with those with minimal tumour burden. The ratio of proportions adjusted for age and anti-emetic treatment was 2.0 (1.0-4.1). In the delayed phase (days 1 -14) no significant association was seen.
The overall effect of age on nausea during the monitoring period is presented in Figure 3 . From about 1 week after the chemotherapy and onwards an increasing trend for more frequent delayed nausea in older (>55 years) patients was observed. For days 9 -13, ratios of proportions adjusted for tumour burden and anti-emetic treatment were 1.2-1.3 with the 95% confidence interval separated from 1.0. This pattern was evident primarily in patients with large tumour burden (Figure 4) . In this group, ratios of proportions adjusted for anti-emetic treatment reached significance for day 7 [RP 1.7 (1.1-2.6)], day 9 [RP 1.5 (1.2-2.0)], day 10 [RP 1.5 (1.1-1.9)], day 11 [RP 1.5 (1.2-2.0)], day 12 [RP 1.3 (1.1-1.6)] and day 13 [RP 1.4 (1.1-1.8)]. In patients with minimal tumour burden, no significant association between age and nausea was observed during the study days. The logistic regression analyses confirmed that tumour burden predicted nausea on the chemotherapy day (P= 0.013) but not in the delayed phase. Age predicted nausea on days 9 -12 (P <0.05). In the analysis using the total anti-emetic response as the outcome (i.e. no delayed nausea on any day), history of motion sickness was the only significant predictor variable (P= 0.0 18). Only 18 of the 101 participating patients totally escaped from delayed nausea and 17 of these lacked the previous history of motion sickness. The analysis of total anti-emetic response describes what happens during days 1 -5 since no patient had her first day of delayed nausea later than day 5.
Interaction between tumour burden and age To illustrate interaction between tumour burden and age further we compared patients with both the risk factors (i.e. tumour burden >2 cm and age >55 years) with those with none. Patients with only one of the two characteristics were treated as one group. The results are presented in Figure 5 (emetic episodes) and Figure 6 (nausea). In both cases the group with large residual tumour burden and higher age clearly differs from the other two groups. The group with only one of the risk factors shows a greater resemblance to those with no risk factor than those with two.
Symptoms in the preceding week The overall rating levels concerning the functional status during the week preceding the chemotherapy were similar to those obtained in a previous study with ovarian cancer patients (Fiirst et al., 1992) . However, the results indicated a more compromised well-being for the patients with large residual tumour burden compared with those with minimal tumour burden (Table II ). Significant differences were found for vomiting, appetite, fatigue, general well-being and (nearly significantly) strength. The patients with large tumour burden were also less satisfied with the information they received concerning their illness and its treatment. We also analysed nausea and vomiting concerning the pure prevalence by dichotomising the ratings in 'not bothered at all' (VAS = 0) and 'bothered' (VAS 1 -100). Vomiting but not nausea was more common in patients with large compared with minimal tumour burden (vomiting, X2 = 7.3, P<0.01; nausea, X2 =0.1, NS). Age was not related to nausea and vomiting during the prechemotherapy period but the older patients complained more about lack of strength and difficulties in relaxation when compared with the younger ones (Table II) . Mean ratings on a 100 mm visual analogue scale for patients categorised by the diameter of the greatest residual tumour (< 2 cm vs > 2 cm) and by age ( < 55 years vs> 55 years). Low ratings correspond to unaffected well-being. Discussion
Our results indicate an association between residual tumour burden and chemotherapy-induced nausea and vomiting. Thus, patients with tumour burden > 2 cm in greatest diameter compared with those with minimal tumour burden reported more frequent emetic episodes in the delayed phase and also, somewhat less articulated, in the acute phase. They experienced more often acute but not delayed nausea. Compared with younger ones, older patients reported more frequent nausea during the second week after the chemotherapy. They also tended to have more frequent emetic episodes during the first days of the chemotherapy cycle. The antiemetic response for delayed emesis (no delayed emesis) was predicted by anti-emetic treatment with dexamethasone, minimal tumour burden, low neuroticism and the lack of history of motion sickness. Likewise, the anti-emetic response for delayed nausea was predicted by the lack of history of motion sickness. There may be several co-existing factors explaining our results. The majority of patients categorised as having large residual tumour burden had an intra-abdominal tumour > 10 cm in greatest diameter. Hypothetically such a tumour mass may exert a mechanical pressure on the gut leading to nausea and vomiting. Alternatively, spontaneous or chemotherapy-induced tumour necrosis may cause a release of substances (e.g. prostaglandins or cytokines) from the tumour and influence nausea and vomiting (Andrews and Davis, 1993) .
During the week preceding the chemotherapy the patients with large residual tumour burden reported vomiting significantly more often accompanied by loss of appetite and strength, increased fatigue and generally inferior wellbeing compared with patients with minimal tumour burden. Hypothetically, this could be explained by the abovementioned mechanisms. As demonstrated in Figures 1 and  2 it seems that in the group of patients with large residual tumour, the rate of complete response does not improve after day 9. This observed difference may to some extent reflect prechemotherapy differences. However, it should be pointed out that none of the patients experienced vomiting 24 h before the start of the chemotherapy.
Older patients, particularly those with large residual tumour burden, reported more frequent side-effects in the delayed phase compared with younger patients. This is in contrast to some previous studies showing an inverse relationship between age and acute nausea and vomiting . The association between age and emesis has not been thoroughly studied during the delayed phase. To our knowledge no previous report has shown age differences in delayed nausea or vomiting (Carmichael et al., 1994; du Bois et al., 1992; Gandara et al., 1993; Italian Group for Antiemetic Research, 1994; Kaizer et al., 1994; Lindley et al., 1989; Roila et al., 1991) . Interestingly, in more recent studies, the evidence provided for an inverse relationship between age and emesis in the acute phase has not been consistent (de Wet et al., 1993; Heron et al., 1994; Italian Group for Antiemetic Research, 1993; Ruff et al., 1994) . This may be related to the introduction of new anti-emetic regimens. The mechanisms mediating the effect of age on nausea and vomiting are not known. However, the association is most likely multifactorially determined and hence modified by several variables.
The combined aggravating effects of tumour burden and age in the delayed phase may also be conceived of as a more general age-dependent problem of recovery (Erschler and Balducci, 1994) . In general, elderly patients recover more slowly after, for example, surgery or an injury (Artinian et al., 1993; Pennings et al., 1993) . The effect of cancer treatment is also less favourable for older patients compared with younger patients (Alberts et al., 1993) . As demonstrated in Figure 4 older patients with tumour seem to recover more slowly from the chemotherapy compared with younger patients (slope of the curve is less steep for older patients).
In conclusion, monitoring nausea and vomiting up to 2 weeks after chemotherapy revealed that while the delayed symptoms decreased exponentially during the first week, there was practically no further improvement during the second week. The results suggest that older patients with large residual tumour burden are at increased risk of this 'persistent' delayed nausea and vomiting. Also, earlier in the delayed phase these patients suffered from more frequent emetic episodes. Large tumour burden was associated with compromised well-being already before the treatment started. This is decremental since persistent nausea and vomiting may lead to a descending spiral with further worsening of functional status (O'Brien et al., 1993) . The impact of 'persistent' delayed nausea on delivered dose intensity of chemotherapy given with a curable intent and well-being when given in a palliative setting warrants further attention.
